Financials in USD. Standardized financial statements.
A compact view of how Neuren Pharmaceuticals Limited turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $64.61M | $216.83M | $231.93M | $14.55M | $3.20M | $717,000 | $495,000 | $13.99M | $631,000 | $3.15M |
| Revenue Growth? | -70.2% | -6.5% | +1493.7% | +355.2% | +345.9% | +44.8% | -96.5% | +2117.1% | -80.0% | 0.0% |
| Cost of Revenue? | $22,989 | $32.97M | $26.75M | $10,000 | $8,000 | $6,000 | $4,000 | $6.10M | $78,000 | $80,000 |
| Gross Profit? | $64.59M | $183.86M | $205.17M | $14.54M | $3.19M | $711,000 | $491,000 | $7.89M | $553,000 | $3.07M |
| Gross Margin? | +100.0% | +84.8% | +88.5% | +99.9% | +99.7% | +99.2% | +99.2% | +56.4% | +87.6% | +97.5% |
| Operating Expenses? | $42.57M | $37.69M | $32.70M | $16.14M | $11.42M | $9.52M | $11.57M | $5.03M | $6.63M | $15.09M |
| Operating Income? | $22.02M | $146.19M | $172.49M | -$1.60M | -$17.75M | -$16.57M | -$11.57M | $5.82M | -$6.70M | -$15.17M |
| EBITDA? | $22.04M | $179.18M | $199.26M | -$722,000 | -$8.22M | -$8.80M | -$11.31M | $5.37M | $2.73M | -$13.78M |
| Income Before Tax | $38.91M | $182.94M | $205.14M | -$680,000 | -$7.79M | -$9.19M | -$11.31M | $3.07M | $2.66M | -$13.86M |
| Income Tax Expense | $8.49M | $40.90M | $48.06M | -$864,000 | $0 | $0 | -$495,000 | $0 | -$631,000 | -$1.84M |
| Net Income? | $30.42M | $142.04M | $157.08M | $184,000 | -$7.79M | -$9.19M | -$10.82M | $3.07M | $3.29M | -$12.01M |
| EPS? | $0.24 | $1.09 | $1.24 | $0.00 | $-0.07 | $-0.09 | $-0.11 | $0.03 | $0.04 | $-2.84 |
| Diluted EPS? | $0.24 | $1.09 | $1.20 | $0.00 | $-0.07 | $-0.09 | $-0.11 | $0.03 | $0.04 | $-2.84 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality